Technical Analysis for RHHVF - Roche Holding AG

Grade Last Price % Change Price Change
grade B 273.69 -1.37% -3.8100
RHHVF closed down 1.37 percent on Friday, August 23, 2019, on 14 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical RHHVF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.37%

Older signals for RHHVF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit
Health Pharmaceuticals Pharmaceutical Industry Life Sciences Diabetes Pharmaceutical Industry In China Infectious Diseases Chemotherapy Neuroscience Antibiotics In Vitro Diagnostics Genentech Hoffmann La Roche Diabetes Management Roche World Health Organization Personalised Healthcare Strategy Research Focused Healthcare Tissue Based Cancer
Is RHHVF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 300.4055
52 Week Low 230.72
Average Volume 4,149
200-Day Moving Average 264.711
50-Day Moving Average 275.3465
20-Day Moving Average 273.9073
10-Day Moving Average 277.5915
Average True Range 4.8119
ADX 17.22
+DI 54.5755
-DI 14.6884
Chandelier Exit (Long, 3 ATRs ) 285.9698
Chandelier Exit (Short, 3 ATRs ) 280.0857
Upper Bollinger Band 282.8741
Lower Bollinger Band 264.9405
Percent B (%b) 0.49
BandWidth 6.547325
MACD Line 1.2329
MACD Signal Line 1.0477
MACD Histogram 0.1852
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 313.8233
Resistance 3 (R3) 318.2692 309.3373 307.1344
Resistance 2 (R2) 309.3373 299.1167 307.1144 304.9030
Resistance 1 (R1) 291.5137 292.8024 287.0478 287.0678 302.6742
Pivot Point 282.5818 282.5818 280.3489 280.3589 282.5818
Support 1 (S1) 264.7582 272.3612 260.2923 260.3123 244.7058
Support 2 (S2) 255.8263 266.0469 253.6034 242.4770
Support 3 (S3) 238.0027 255.8263 240.2456
Support 4 (S4) 233.5568